Development and validation of a novel HER2RI assay for predicting the risk of recurrence and survival in HER2-positive early breast cancer

Yi‐Kun Kang(Chinese Academy of Medical Sciences & Peking Union Medical College), Peng Yuan(Chinese Academy of Medical Sciences & Peking Union Medical College), Ouchen Wang(Wenzhou Medical University), Singlin Gao(Chinese Academy of Medical Sciences & Peking Union Medical College), Jian Yue(Chinese Academy of Medical Sciences & Peking Union Medical College), Furong Du(Simcere Pharmaceutical (China)), Huimin Wang(Simcere Pharmaceutical (China)), Xue Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaojia Wang(Wenzhou Medical University), Keyu Chen(Ningbo University), Jianmin Li(Wenzhou Medical University), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Ting‐Hao Chen(National Taiwan University), Shangzhi Cao(Simcere Pharmaceutical (China))
Research Square
August 19, 2022
10.21203/rs.3.rs-1964372/v1
Cited by 0

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
|Annals of Oncology|2021|799
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743